Line 11: |
Line 11: |
| ! REFERENCES | | ! REFERENCES |
| |- | | |- |
− | ! GLIOMAS
| + | | GLIOMAS |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |WHO CNS Tumors (2016) |
| |- | | |- |
| | Low grade glioma, WHO grade I | | | Low grade glioma, WHO grade I |
Line 179: |
Line 184: |
| |- | | |- |
| | | | | |
| + | |Group3 |
| + | |'''Gain:''' 1q, 7, 18q<br> |
| + | '''Loss:''' 5q, 8, 10q, 11p, 16q<br> |
| + | '''Rearrangement:''' idic(17)(p11.2)<br> |
| + | '''Ploidy changes:''' tetraploidy in 40-50% of Group3/Group4 tumors |
| + | |'''Mutation/Amplification:''' MYC (mainly in infants), OTX2, CDK6, SMARC4A, CTDNEP1, LRP1B, KMT2D<br> |
| + | '''Fusions:''' PVT1-MYC, PVT1-NDRG1; GFI1/GFI1B structural variants |
| + | |Usually classic histology, ~ 50% are metastatic at time of diagnosis, Not generally observed in adults |
| + | |PMID:22832581, PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768 PMID:20940197; PMID:23175120 |
| + | |- |
| | | | | |
| + | |Group4 |
| + | |'''Gain:''' 7, 18q<br> |
| + | '''Loss:''' X, 8, 11p<br> |
| + | '''Rearrangement:''' idic(17)(p11.2) in >80%<br> |
| + | '''Chromothripsis:''' rare, but associated with TP53 loss when observed |
| + | |'''Mutation:''' TP53, KDM6A, KMT2C <br> |
| + | '''Amplification:''' MYCN, CDK4, CDK6, OTX2<br> |
| + | '''Rearrangement:''' SNCAIP tandem duplication; GFI1/GFI1B structural variants |
| + | |Rarely seen in infants; usually classic histology |
| + | |PMID:22832581; PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768 PMID:20940197 PMID:23175120 |
| + | |- |